Detail akcie Monte Rosa Therp Rg online

Business Summary: Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Monte Rosa Therapeutics Inc revenues increased from $15M to $120.9M. Net income totaled $7.5M vs. loss of $86.1M. Revenues reflect components of an entity segment increase from $5.8M to $120.9M. Net Income reflects components of an entity segment loss decrease of 93% to $4.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.25 to $0.09.